Eli Lilly and Co
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Study of LY3454738 in Adults With Chronic Spontaneous Urticaria
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- Drug: LY3454738Drug: Placebo
- First Posted Date
- 2019-11-12
- Last Posted Date
- 2022-03-11
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 52
- Registration Number
- NCT04159701
- Locations
- 🇺🇸
California Allergy and Asthma Medical Group + Research Center, Los Angeles, California, United States
🇺🇸Miami Dermatology and Laser Research, Miami, Florida, United States
🇺🇸Kern Research, Inc, Bakersfield, California, United States
A Study of LY3556050 in Healthy Participants
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2019-11-07
- Last Posted Date
- 2020-08-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 34
- Registration Number
- NCT04156750
- Locations
- 🇺🇸
Covance, Dallas, Texas, United States
A Study of Insulin Glargine (LY2963016) in Adult Participants With Type 2 Diabetes in India
- First Posted Date
- 2019-11-06
- Last Posted Date
- 2024-02-15
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 304
- Registration Number
- NCT04153981
- Locations
- 🇮🇳
Government Medical College & Sir Sayajirao General Hospital, Vadodara, Gujarat, India
🇮🇳Gujarat Endocrine Center, Ahmedabad, Gujarat, India
🇮🇳DIACARE, Ahemdabad, Gujarat, India
A Safety Study of LY3462817 and LY3509754 in Participants With Psoriasis
- Conditions
- Psoriasis
- Interventions
- Drug: LY3462817 - IVDrug: Placebo - IVDrug: LY3462817 - SCDrug: Placebo - SCDrug: LY3509754Drug: Placebo
- First Posted Date
- 2019-11-05
- Last Posted Date
- 2022-03-15
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 30
- Registration Number
- NCT04152382
- Locations
- 🇨🇦
K. Papp Clinical Research, Waterloo, Ontario, Canada
🇺🇸Progressive Clinical Research, San Antonio, Texas, United States
🇺🇸Meridian Clinical Research, Baton Rouge, Louisiana, United States
A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer
- First Posted Date
- 2019-11-04
- Last Posted Date
- 2024-04-05
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 52
- Registration Number
- NCT04148937
- Locations
- 🇬🇧
Beatson West of Scotland Cancer Center, Glasgow, Scotland, United Kingdom
🇬🇧Royal Marsden NHS Trust, Sutton, United Kingdom
🇬🇧Addenbrookes Hospital, Cambridge, Cambridgeshire, United Kingdom
CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma
- Conditions
- Synovial Sarcoma
- Interventions
- First Posted Date
- 2019-10-31
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 23
- Registration Number
- NCT04145700
- Locations
- 🇺🇸
Childrens Hospital of Los Angeles, Los Angeles, California, United States
🇺🇸Children's Medical Center Dallas, Dallas, Texas, United States
🇺🇸Ann & Robert H Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1)
- Conditions
- Atopic Dermatitis
- Interventions
- Biological: LebrikizumabOther: Placebo
- First Posted Date
- 2019-10-31
- Last Posted Date
- 2022-11-30
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 424
- Registration Number
- NCT04146363
- Locations
- 🇱🇻
Latvian Dermatology Institute, Riga, Latvia
🇱🇹JSC "CD8 Alergology Clinic", Kaunas, Lithuania
🇪🇸Sant Joan de Deu Serveis En Salut Mental, SANT BOI DE Llobrega, Barcelona, Spain
CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor
- Conditions
- Desmoplastic Small Round Cell Tumor
- Interventions
- First Posted Date
- 2019-10-30
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 34
- Registration Number
- NCT04145349
- Locations
- 🇺🇸
Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸Childrens Hospital of Los Angeles, Los Angeles, California, United States
🇺🇸Children's National Medical Center, Washington, District of Columbia, United States
A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM)
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2019-10-29
- Last Posted Date
- 2021-01-20
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 72
- Registration Number
- NCT04143802
- Locations
- 🇺🇸
Clinical Trials of Texas, Inc., San Antonio, Texas, United States
🇺🇸Anaheim Clinical Trials, LLC, Anaheim, California, United States
🇺🇸PRA International, Lenexa, Kansas, United States
A Study of Mirikizumab in Healthy Chinese Participants
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2019-10-24
- Last Posted Date
- 2024-01-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 60
- Registration Number
- NCT04137380
- Locations
- 🇨🇳
Shanghai Xuhui Central Hospital, Xuhui District, Shanghai, China
🇨🇳Peking University First Hospital, Beijing, China